One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration
Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.
Authors
- Ayesha Ahmed
- Theodore Leng (ORCID: https://orcid.org/0000-0002-8461-3562)
- Alayna C Myrick
- Erin Zwick (ORCID: https://orcid.org/0000-0001-7174-198X)
- Giulio Barteselli (ORCID: https://orcid.org/0000-0003-0533-1135)
- R. Paul Singh (ORCID: https://orcid.org/0000-0001-5529-4294)
- Ferhina S. Ali
- Stella Ko
- Durga Borkar
- Amanda Downey
- David C. Tabano
Institutions
- Cleveland Clinic (US)
- Duke University (US)
- New York Medical College (US)
- Roche (Canada) (CA)
- University School (US)
- Cleveland Eye Clinic (US)
- Smith-Kettlewell Eye Research Institute (US)
- Martin Health System (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Ophthalmic surgery, lasers & imaging retina
- Published
- 2026-03-27
- DOI
- https://doi.org/10.3928/23258160-20260302-02
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00